developed a model composed by four biomarkers (Il-2, TNFR1, IL-8, and HGF) for the laboratory confirmation of GvHD and its prognostic stratification In the same line, and using proteomics approaches, the Mount Sinai Acute GVHD International Consortium (MAGIC) went a step further and validated an algorithm for the prediction of the risk of severe GvHD, non-relapse mortality (NRM) (141) and long-term outcomes in patients with steroid-refractory GVHD (142). This evidence concerns the gene TNFRSF1A and acute graft versus host disease.